Literature DB >> 28446805

Biomarkers for right-sided heart failure.

Masayuki Tanemoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28446805     DOI： 10.1038/hr.2017.58

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  4 in total

1.  The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.

Authors:  Sarah Seiler; Bodo Cremers; Niko M Rebling; Florian Hornof; Jana Jeken; Sylvie Kersting; Charlotte Steimle; Philipp Ege; Michael Fehrenz; Kyrill S Rogacev; Bruno Scheller; Michael Böhm; Danilo Fliser; Gunnar H Heine
Journal:  Eur Heart J       Date:  2011-07-06       Impact factor: 29.983

2.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.

Authors:  Wilfried Mullens; Zuheir Abrahams; Gary S Francis; George Sokos; David O Taylor; Randall C Starling; James B Young; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2009-02-17       Impact factor: 24.094

3.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

4.  Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure.

Authors:  Miki Imazu; Hiroyuki Takahama; Makoto Amaki; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hideaki Kanzaki; Toshihisa Anzai; Naoki Mochizuki; Hiroshi Asanuma; Masanori Asakura; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2016-09-29       Impact factor: 3.872
  4 in total
  1 in total

1.  Reply to 'Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure'.

Authors:  Miki Imazu; Hiroyuki Takahama; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2017-04-27       Impact factor: 3.872
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.